2. Academic Validation
  3. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors

MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors

  • Neuro Oncol. 2020 Jan 11;22(1):58-69. doi: 10.1093/neuonc/noz151.
Michaël H Meel 1 2,  Miriam Guillén Navarro 1,  Mark C de Gooijer 3,  Dennis S Metselaar 1 2,  Piotr Waranecki 1 2,  Marjolein Breur 4,  Tonny Lagerweij 5,  Laurine E Wedekind 5,  Jan Koster 6,  Marianne D van de Wetering 2 7,  Netteke Schouten-van Meeteren 2 7,  Eleonora Aronica 8,  Olaf van Tellingen 3,  Marianna Bugiani 4,  Timothy N Phoenix 9,  Gertjan J L Kaspers 1 2,  Esther Hulleman 1 2
Affiliations

Affiliations

  • 1 Departments of Pediatric Oncology/Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands.
  • 2 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • 3 Division of Pharmacology/Mouse Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • 4 Department of Pathology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
  • 5 Department of Neurosurgery, Neuro-oncology Research Group, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands.
  • 6 Department of Oncogenomics, Amsterdam University Medical Centers, Amsterdam, Netherlands.
  • 7 Department of Pediatric Oncology, Academic Medical Center, Emma Children's Hospital, Amsterdam, Netherlands.
  • 8 Department of (Neuro) Pathology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.
  • 9 Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati/Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
PMID: 31504799 DOI: 10.1093/neuonc/noz151
Abstract

Background: Atypical teratoid/rhabdoid tumors (AT/RT) are rare, but highly aggressive. These entities are of embryonal origin occurring in the central nervous system (CNS) of young children. Molecularly these tumors are driven by a single hallmark mutation, resulting in inactivation of SMARCB1 or SMARCA4. Additionally, activation of the MAPK signaling axis and preclinical antitumor efficacy of its inhibition have been described in AT/RT.

Methods: We established and validated a patient-derived neurosphere culture and xenograft model of sonic Hedgehog (SHH) subtype AT/RT, at diagnosis and relapse from the same patient. We set out to study the vascular phenotype of these tumors to evaluate the integrity of the blood-brain barrier (BBB) in AT/RT. We also used the model to study combined mitogen-activated protein kinase kinase (MEK) and maternal embryonic leucine zipper kinase (MELK) inhibition as a therapeutic strategy for AT/RT.

Results: We found MELK to be highly overexpressed in both patient samples of AT/RT and our primary cultures and xenografts. We identified a potent antitumor efficacy of the MELK Inhibitor OTSSP167, as well as strong synergy with the MEK Inhibitor trametinib, against primary AT/RT neurospheres. Additionally, vascular phenotyping of AT/RT patient material and xenografts revealed significant BBB aberrancies in these tumors. Finally, we show in vivo efficacy of the non-BBB penetrable drugs OTSSP167 and trametinib in AT/RT xenografts, demonstrating the therapeutic implications of the observed BBB deficiencies and validating MEK/MELK inhibition as a potential treatment.

Conclusion: Altogether, we developed a combination treatment strategy for AT/RT based on MEK/MELK inhibition and identify therapeutically exploitable BBB deficiencies in these tumors.

Keywords

atypical teratoid/rhabdoid tumor; blood-brain barrier; maternal embryonic leucine zipper kinase; preclinical therapy development; tumor models.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z